+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Subcutaneous Immunoglobulin - Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • October 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5310771
The global market for Subcutaneous Immunoglobulin was estimated at US$6.4 Billion in 2023 and is projected to reach US$15.6 Billion by 2030, growing at a CAGR of 13.7% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Subcutaneous Immunoglobulin Market - Key Trends & Drivers Summarized

What Is Subcutaneous Immunoglobulin and Why Is It Crucial for Immunodeficiency Treatment?

Subcutaneous Immunoglobulin (SCIg) is a therapeutic preparation of immunoglobulins administered through the subcutaneous route, typically used for the treatment of primary immunodeficiency diseases (PIDs), secondary immunodeficiencies, and certain autoimmune disorders. SCIg provides the body with a concentrated dose of antibodies, derived from pooled human plasma, to help strengthen the immune system's response to infections and other diseases. This form of immunoglobulin therapy is designed for regular administration, usually weekly or biweekly, allowing patients to maintain stable antibody levels and reduce the risk of recurrent infections. SCIg is often preferred over intravenous immunoglobulin (IVIg) due to its ease of use, reduced risk of systemic side effects, and the potential for home-based administration, which enhances patient comfort and compliance.

The global adoption of SCIg is driven by its efficacy in providing long-term immune support and its ability to improve the quality of life for individuals with chronic immunodeficiency conditions. Primary immunodeficiency diseases, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), impair the body's ability to produce adequate antibodies, making patients susceptible to frequent and severe infections. SCIg therapy compensates for this deficiency by delivering a steady supply of antibodies that help protect against bacterial, viral, and fungal pathogens. Additionally, SCIg is increasingly being used to treat secondary immunodeficiencies caused by underlying diseases or immunosuppressive therapies, such as in patients undergoing chemotherapy or those with HIV. The rising prevalence of immunodeficiency disorders, coupled with the growing demand for convenient and effective treatment options, is driving the growth of the SCIg market as healthcare providers seek to improve patient outcomes and reduce the burden of disease.

How Are Technological Advancements Shaping the Development and Delivery of Subcutaneous Immunoglobulin Therapies?

Technological advancements are significantly enhancing the development, formulation, and delivery of subcutaneous immunoglobulin therapies, making them more effective, user-friendly, and accessible for a broader patient population. One of the most impactful innovations in this field is the development of advanced SCIg formulations with improved stability, concentration, and tolerability. Modern SCIg products are being designed with higher protein concentrations, allowing for lower injection volumes and shorter infusion times, which enhance patient convenience and adherence to treatment regimens. The use of stabilizing agents, such as sugars or amino acids, in SCIg formulations is improving the stability and shelf life of these products, ensuring consistent therapeutic efficacy. Additionally, the development of hypoallergenic SCIg formulations with reduced levels of IgA and other potential immunogenic components is minimizing the risk of adverse reactions, making SCIg therapy safer for patients with sensitivities or allergies to certain plasma proteins.

Another key technological advancement driving the SCIg market is the innovation in infusion devices and delivery systems. Traditional SCIg administration involved the use of manual syringes or infusion pumps, which could be cumbersome and time-consuming for patients. Modern SCIg therapies are now available with advanced infusion devices, such as wearable pumps and needle-free injectors, that simplify the administration process and allow for more precise control over infusion rates. These devices are often compact, portable, and easy to use, enabling patients to self-administer SCIg at home with minimal assistance. Wearable devices, such as on-body pumps, allow for continuous or controlled-rate infusion, reducing the frequency of infusions and improving patient comfort. Additionally, innovations in needle technology, such as the development of ultra-fine needles and multi-needle sets, are minimizing injection pain and discomfort, enhancing the overall patient experience. These advancements are making SCIg therapy more accessible and convenient, supporting its adoption in home-based care settings and improving patient quality of life.

Furthermore, advancements in digital health and remote monitoring technologies are enhancing the management and delivery of SCIg therapy. Digital health tools, such as mobile apps and connected devices, are being integrated with SCIg delivery systems to provide real-time monitoring of infusion parameters, track treatment adherence, and offer personalized support to patients. These tools allow healthcare providers to remotely monitor patients' progress, identify potential issues, and adjust treatment plans as needed, reducing the need for frequent clinic visits. The use of telemedicine and virtual consultations is further supporting the adoption of home-based SCIg therapy by providing patients with access to specialist care and guidance from the comfort of their homes. These technological advancements are improving the safety, efficiency, and patient-centeredness of SCIg therapy, making it a more attractive option for individuals with chronic immunodeficiency conditions.

What Factors Are Driving the Adoption of Subcutaneous Immunoglobulin Therapy Across Different Patient Populations and Regions?

The adoption of subcutaneous immunoglobulin therapy is being driven by several key factors, including the growing prevalence of primary and secondary immunodeficiencies, the increasing awareness and diagnosis of immunodeficiency disorders, and the rising preference for home-based treatment options. One of the primary drivers is the growing prevalence of primary and secondary immunodeficiencies worldwide. Primary immunodeficiencies are a group of over 400 rare, inherited disorders that affect the immune system's ability to function properly. The increasing recognition and diagnosis of these conditions, along with improvements in genetic testing and screening, are contributing to a larger patient population eligible for immunoglobulin replacement therapy. Similarly, secondary immunodeficiencies, which can result from medical treatments such as chemotherapy, organ transplantation, or chronic infections, are becoming more common due to the rising incidence of cancer and autoimmune diseases. SCIg therapy is being adopted as an effective treatment option for these patients, providing them with a continuous supply of antibodies to support immune function and reduce the risk of infections.

Another significant factor driving the adoption of SCIg therapy is the increasing awareness and diagnosis of immunodeficiency disorders. Greater awareness among healthcare providers, patients, and caregivers about the signs and symptoms of immunodeficiencies is leading to earlier diagnosis and timely intervention with SCIg therapy. Patient advocacy organizations, such as the Immune Deficiency Foundation (IDF) and the International Patient Organization for Primary Immunodeficiencies (IPOPI), are playing a crucial role in educating the public and promoting early detection and treatment. The availability of comprehensive treatment guidelines and consensus statements from medical societies is also supporting the adoption of SCIg as a standard of care for eligible patients. This growing awareness is particularly strong in developed regions such as North America and Europe, where healthcare systems are well-equipped to diagnose and manage rare and complex immunological conditions. As more patients receive accurate diagnoses and are educated about their treatment options, the demand for SCIg therapy is expected to rise, supporting the growth of the market.

Moreover, the rising preference for home-based treatment options is influencing the adoption of SCIg therapy across various regions. Unlike intravenous immunoglobulin (IVIg), which is typically administered in a hospital or clinical setting, SCIg can be self-administered by patients or caregivers at home, offering greater flexibility and convenience. Home-based SCIg therapy reduces the need for frequent clinic visits, minimizes the risk of hospital-acquired infections, and allows patients to integrate treatment into their daily routines. This home-based approach is particularly beneficial for pediatric patients, elderly patients, and those with mobility issues, as it reduces the physical and logistical burden associated with frequent travel to healthcare facilities. The COVID-19 pandemic has further accelerated the adoption of home-based therapies, as patients and healthcare providers seek to minimize in-person interactions and reduce exposure risks. The growing acceptance of home-based SCIg therapy is driving demand for user-friendly delivery systems and digital health tools that support patient self-management and improve adherence.

What Is Driving the Growth of the Global Subcutaneous Immunoglobulin Market?

The growth in the global Subcutaneous Immunoglobulin (SCIg) market is driven by several factors, including rising investments in research and development (R&D), the increasing adoption of advanced SCIg delivery systems, and the growing focus on personalized medicine and patient-centered care. One of the primary growth drivers is the rising investment in R&D activities aimed at developing novel SCIg formulations and delivery devices. Leading biopharmaceutical companies are investing heavily in the development of high-concentration SCIg products, long-acting formulations, and novel stabilizing agents that enhance the safety and efficacy of SCIg therapy. The focus on R&D is also leading to the introduction of new indications for SCIg, such as its use in chronic inflammatory demyelinating polyneuropathy (CIDP) and other neurological conditions, expanding the therapeutic applications of SCIg beyond immunodeficiency. Clinical trials and post-marketing studies are providing evidence of the benefits of SCIg therapy in diverse patient populations, supporting its adoption as a first-line treatment option for eligible patients. These R&D efforts are supporting the growth of the SCIg market by providing patients and healthcare providers with innovative treatment options that improve outcomes and quality of life.

Another significant driver of market growth is the increasing adoption of advanced SCIg delivery systems. The development of user-friendly, portable, and wearable SCIg infusion devices is making it easier for patients to self-administer therapy at home. Devices such as wearable pumps, smart infusion systems, and needle-free injectors are simplifying the administration process and allowing for more precise control over infusion parameters. The use of electronic and smart devices that provide feedback, track infusion progress, and alert patients or caregivers in case of issues is further enhancing the safety and convenience of SCIg therapy. These advanced delivery systems are reducing the learning curve associated with SCIg administration and making it more accessible to a wider patient population, including those with limited experience in self-care. The increasing availability of these devices, along with the expansion of home healthcare services, is driving the adoption of SCIg therapy and supporting the growth of the market.

Moreover, the growing focus on personalized medicine and patient-centered care is supporting the growth of the SCIg market. Personalized medicine involves tailoring treatment plans to the individual needs and preferences of each patient, taking into account factors such as disease severity, lifestyle, and response to therapy. SCIg therapy, with its flexibility in dosing and administration schedules, is well-suited for personalized treatment approaches. Healthcare providers can adjust the dose, frequency, and site of administration based on the patient's clinical response and preferences, optimizing therapeutic outcomes. The use of digital health tools, such as mobile apps and connected devices, is further enabling personalized care by providing real-time data on treatment adherence, patient-reported outcomes, and infusion parameters. These tools allow for more precise and individualized treatment management, supporting better patient engagement and satisfaction. The growing emphasis on personalized medicine is driving demand for SCIg therapies that offer flexibility, convenience, and patient-centeredness, supporting the expansion of the market.

Furthermore, the increasing demand for safe and effective alternatives to IVIg therapy is influencing the growth of the SCIg market. While IVIg remains a standard treatment for many immunodeficiency and autoimmune conditions, it requires intravenous access and close monitoring, which can be challenging for some patients. SCIg offers a more convenient alternative that can be administered at home with a lower risk of systemic side effects, such as headaches, fever, and infusion-related reactions. The development of high-concentration SCIg products is allowing for reduced infusion volumes and shorter administration times, making SCIg a viable option for patients who prefer less invasive and time-consuming therapies. The increasing preference for SCIg over IVIg is driving the growth of the SCIg market, as patients and healthcare providers seek treatment options that offer improved quality of life and ease of use. As these factors continue to shape the global healthcare landscape, the Subcutaneous Immunoglobulin market is expected to experience robust growth, driven by rising investments in R&D, the increasing adoption of advanced SCIg delivery systems, and the growing focus on personalized medicine and patient-centered care.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Primary Immunodeficiency Diseases Application segment, which is expected to reach US$12.0 Billion by 2030 with a CAGR of a 14.7%. The Secondary Immunodeficiency Diseases Application segment is also set to grow at 10.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $1.7 Billion in 2023, and China, forecasted to grow at an impressive 12.9% CAGR to reach $2.4 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Subcutaneous Immunoglobulin Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Subcutaneous Immunoglobulin Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Subcutaneous Immunoglobulin Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players in the Subcutaneous Immunoglobulin market such as Biotest AG, CSL Behring, Grifols International SA, Grifols SA, Kedrion SpA and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 46 companies featured in this Subcutaneous Immunoglobulin market report include:

  • Biotest AG
  • CSL Behring
  • Grifols International SA
  • Grifols SA
  • Kedrion SpA
  • Octapharma AG
  • Shire PLC

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Subcutaneous Immunoglobulin - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Immunodeficiency Disorders Drives Demand for Subcutaneous Immunoglobulin
  • Increased Adoption of Home-Based Infusion Therapy Fuels Market Growth
  • Expansion of Specialty Pharmacy Networks Sets the Stage for Market Growth
  • Rising Awareness of Immunoglobulin Therapy Among Patients and Healthcare Providers Fuels Demand
  • Surge in Demand for Subcutaneous Immunoglobulin for Neurological Disorders Expands Market Opportunities
  • Rising Adoption of Subcutaneous Immunoglobulin in Rare Disease Management Sets the Stage for Market Growth
  • Increased Focus on Reducing Hospitalization and Healthcare Costs Fuels Demand for Home-Based Immunoglobulin Therapies
  • Surge in Demand for Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Fuels Market Growth
  • Growing Preference for Self-Administration and Self-Care Solutions Expands Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Subcutaneous Immunoglobulin Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Subcutaneous Immunoglobulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Subcutaneous Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Primary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Primary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Primary Immunodeficiency Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Secondary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Secondary Immunodeficiency Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Secondary Immunodeficiency Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 15: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 18: World Historic Review for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: World 16-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Subcutaneous Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 20: USA Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: USA Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: USA 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 23: USA Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: USA Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: USA 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Canada 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 29: Canada Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Canada 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
JAPAN
  • Subcutaneous Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 32: Japan Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: Japan Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: Japan 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 35: Japan Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Japan 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
CHINA
  • Subcutaneous Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 38: China Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: China Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: China 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 41: China Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: China Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: China 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
EUROPE
  • Subcutaneous Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 44: Europe Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 45: Europe Historic Review for Subcutaneous Immunoglobulin by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Europe 16-Year Perspective for Subcutaneous Immunoglobulin by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 47: Europe Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Europe 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Europe 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
FRANCE
  • Subcutaneous Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 53: France Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 54: France Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: France 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 56: France Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: France Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: France 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
GERMANY
  • Subcutaneous Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 59: Germany Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 60: Germany Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 61: Germany 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 62: Germany Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 64: Germany 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
ITALY
  • Table 65: Italy Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 66: Italy Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 67: Italy 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 68: Italy Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 70: Italy 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Subcutaneous Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 71: UK Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 72: UK Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 73: UK 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 74: UK Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 75: UK Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 76: UK 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 77: Rest of Europe Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 78: Rest of Europe Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 79: Rest of Europe 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 80: Rest of Europe Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 81: Rest of Europe Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 82: Rest of Europe 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Subcutaneous Immunoglobulin Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 83: Asia-Pacific Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 84: Asia-Pacific Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 85: Asia-Pacific 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 86: Asia-Pacific Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 87: Asia-Pacific Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 88: Asia-Pacific 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
REST OF WORLD
  • Table 89: Rest of World Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 90: Rest of World Historic Review for Subcutaneous Immunoglobulin by Application - Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 91: Rest of World 16-Year Perspective for Subcutaneous Immunoglobulin by Application - Percentage Breakdown of Value Sales for Primary Immunodeficiency Diseases and Secondary Immunodeficiency Diseases for the Years 2014, 2024 & 2030
  • Table 92: Rest of World Recent Past, Current & Future Analysis for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 93: Rest of World Historic Review for Subcutaneous Immunoglobulin by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 94: Rest of World 16-Year Perspective for Subcutaneous Immunoglobulin by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2024 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Biotest AG
  • CSL Behring
  • Grifols International SA
  • Grifols SA
  • Kedrion SpA
  • Octapharma AG
  • Shire PLC

Table Information